Son of Darzalex hits the skids
J&J decides not to opt in to erzotabart, and Genmab pulls the plug.
Regeneron’s lung cancer Lag3 lag
Fianlimab NSCLC data are delayed, while odronextamab gets a DLBCL blow.
ASH 2024 – Arcellx is happy to share in Car-T
Much has been made of anito-cel’s rivalry with Carvykti, but Arcellx reckons there’s plenty of market for both.
ASH 2024 – CellCentric's myeloma first
Inobrodib's first substantial multiple myeloma dataset suggests late-line promise.
ASH 2024 – J&J aims at a myeloma precursor
The Aquila study could make Darzalex the first approved drug for smouldering multiple myeloma.
ASH 2024 – AbbVie fights to rise above the BCMA crowd
Etentamig is one of several anti-BCMA T-cell engagers seeking attention at ASH.
Roche doubles down on Poseida
A $1bn buyout gives Roche more allogeneic Car-T projects, plus non-viral gene therapy contenders.
